344 related articles for article (PubMed ID: 20421463)
1. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.
DeVincenzo J; Lambkin-Williams R; Wilkinson T; Cehelsky J; Nochur S; Walsh E; Meyers R; Gollob J; Vaishnaw A
Proc Natl Acad Sci U S A; 2010 May; 107(19):8800-5. PubMed ID: 20421463
[TBL] [Abstract][Full Text] [Related]
2. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
Zamora MR; Budev M; Rolfe M; Gottlieb J; Humar A; Devincenzo J; Vaishnaw A; Cehelsky J; Albert G; Nochur S; Gollob JA; Glanville AR
Am J Respir Crit Care Med; 2011 Feb; 183(4):531-8. PubMed ID: 20851929
[TBL] [Abstract][Full Text] [Related]
3. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.
Alvarez R; Elbashir S; Borland T; Toudjarska I; Hadwiger P; John M; Roehl I; Morskaya SS; Martinello R; Kahn J; Van Ranst M; Tripp RA; DeVincenzo JP; Pandey R; Maier M; Nechev L; Manoharan M; Kotelianski V; Meyers R
Antimicrob Agents Chemother; 2009 Sep; 53(9):3952-62. PubMed ID: 19506055
[TBL] [Abstract][Full Text] [Related]
4. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients.
Gottlieb J; Zamora MR; Hodges T; Musk AW; Sommerwerk U; Dilling D; Arcasoy S; DeVincenzo J; Karsten V; Shah S; Bettencourt BR; Cehelsky J; Nochur S; Gollob J; Vaishnaw A; Simon AR; Glanville AR
J Heart Lung Transplant; 2016 Feb; 35(2):213-21. PubMed ID: 26452996
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).
DeVincenzo J; Cehelsky JE; Alvarez R; Elbashir S; Harborth J; Toudjarska I; Nechev L; Murugaiah V; Van Vliet A; Vaishnaw AK; Meyers R
Antiviral Res; 2008 Mar; 77(3):225-31. PubMed ID: 18242722
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
[TBL] [Abstract][Full Text] [Related]
7. A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
Nilsson AC; Pullman J; Napora P; Luz K; Gupta A; Draghi J; Guzman Romero AK; Aggarwal N; Petrova G; Ianus J; Vijgen L; Scott J; Sinha R; Rusch S; Huntjens D; Bertzos K; Stevens M;
Clin Microbiol Infect; 2023 Oct; 29(10):1320-1327. PubMed ID: 37422079
[TBL] [Abstract][Full Text] [Related]
8. CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
Ferrero F; Lin CY; Liese J; Luz K; Stoeva T; Nemeth A; Gijón M; Calvo C; Natalini S; Toh TH; Deleu S; Chen B; Rusch S; Sánchez BL; Leipoldt I; Vijgen L; Huntjens D; Baguet T; Bertzos K; Gamil M; Stevens M;
Paediatr Drugs; 2024 Jul; 26(4):411-427. PubMed ID: 38649595
[TBL] [Abstract][Full Text] [Related]
9. ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation.
González-Sanz R; Mata M; Bermejo-Martín J; Álvarez A; Cortijo J; Melero JA; Martínez I
J Virol; 2016 Jan; 90(7):3428-38. PubMed ID: 26763998
[TBL] [Abstract][Full Text] [Related]
10. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
Stevens M; Rusch S; DeVincenzo J; Kim YI; Harrison L; Meals EA; Boyers A; Fok-Seang J; Huntjens D; Lounis N; Mari N K; Remmerie B; Roymans D; Koul A; Verloes R
J Infect Dis; 2018 Jul; 218(5):748-756. PubMed ID: 29684148
[TBL] [Abstract][Full Text] [Related]
12. Design and validation of small interfering RNA on respiratory syncytial virus M2-2 gene: A potential approach in RNA interference on viral replication.
Chin VK; Atika Aziz NA; Hudu SA; Harmal NS; Syahrilnizam A; Jalilian FA; Zamberi S
J Virol Methods; 2016 Oct; 236():117-125. PubMed ID: 27432115
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children.
Rodriguez WJ; Gruber WC; Groothuis JR; Simoes EA; Rosas AJ; Lepow M; Kramer A; Hemming V
Pediatrics; 1997 Dec; 100(6):937-42. PubMed ID: 9374560
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
[TBL] [Abstract][Full Text] [Related]
15. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
DeVincenzo JP; McClure MW; Symons JA; Fathi H; Westland C; Chanda S; Lambkin-Williams R; Smith P; Zhang Q; Beigelman L; Blatt LM; Fry J
N Engl J Med; 2015 Nov; 373(21):2048-58. PubMed ID: 26580997
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
[TBL] [Abstract][Full Text] [Related]
17. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
18. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant.
Gottlieb J; Torres F; Haddad T; Dhillon G; Dilling DF; Knoop C; Rampolla R; Walia R; Ahya V; Kessler R; Budev M; Neurohr C; Glanville AR; Jordan R; Porter D; McKevitt M; German P; Guo Y; Chien JW; Watkins TR; Zamora MR
J Heart Lung Transplant; 2023 Jul; 42(7):908-916. PubMed ID: 36964084
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
